Fezolinetant was linked to VMS and sleep improvements by week 4 in the real-world OPTION-VMS study, presented at the International Menopause Society World Congress.

Psychotherapy addresses fear and anxiety that can blunt hormone and pelvic floor therapy in menopause care, according to Sheryl Kingsberg, PhD.

Get caught up with Contemporary OB/GYN! This list helps you navigate our top stories from the week, all in one place.

Fezolinetant (Veozah) was linked to objective and patient-reported sleep gains in OPTION-VMS, with no new safety signals observed.

Wen Shen, MD, explains how clinicians can counter menopause misinformation from social media and steer patients toward evidence-based resources.

Wen Shen, MD, outlines when to treat perimenopausal symptoms and which history-taking red flags should prompt earlier bone and cardiovascular screening or referral.

Jean Cunningham, PharmD, BCPS, explains how ob-gyns can link anxiety, sleep disruption, and cognitive changes to perimenopause—and catch it earlier.

Marla Shapiro, MDCM, explains how OPTION-VMS actigraphy data corroborated patient-reported sleep improvements with fezolinetant (Veozah) as early as week 4.